Inamed CEO (Chief Executive Officer) defends silicone for breast implants
This article was originally published in Clinica
The co-CEO of Inamed, one of the two major US manufacturers of breast implants and the company which inherited the liability for the failed soya oil filled implants used in Europe, has explained why he believes that silicone gel should be re-introduced as a filler in the US market. He has defended the company's clinical trials with the product and its attempt to gain US FDA approval, despite silicone's history of leakage and possible health damage.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.